Precision BioSciences DTIL shares are trading higher after the company reported its ARCUS platform showed a promising gene editing approach for transthyretin amyloidosis.
"We're excited about the growing body of data demonstrating this ‘one and done' approach with ARCUS, and what it may mean for transforming the treatment of rare genetic diseases in humans," said Derek Jantz, Chief Scientific Officer and co-founder of Precision BioSciences.
Precision BioSciences is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions.
The stock was trading 12.14% higher at $9.05 per share at the time of writing. The stock has a 52-week high of $16.60 and a 52-week low of $4.45.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
